Spero Therapeutics (NASDAQ:SPRO) Shares Pass Below 200 Day Moving Average – Time to Sell?

Spero Therapeutics, Inc. (NASDAQ:SPRO) passed below its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $2.41 and traded as low as $1.08. Spero Therapeutics shares last traded at $1.19, with a volume of 11,754,579 shares trading hands.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on SPRO. Weiss Ratings reissued a “sell (d-)” rating on shares of Spero Therapeutics in a research report on Friday, July 17th. Wall Street Zen cut Spero Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Saturday, May 16th. One analyst has rated the stock with a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Spero Therapeutics presently has a consensus rating of “Reduce”.

Spero Therapeutics Trading Up 2.6%

The firm has a market cap of $68.90 million, a P/E ratio of 4.96 and a beta of 1.49. The business’s 50-day moving average is $2.31 and its two-hundred day moving average is $2.41.

Spero Therapeutics (NASDAQ:SPRO) last issued its earnings results on Wednesday, May 13th. The company reported ($0.13) EPS for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.05. The company had revenue of $0.26 million during the quarter, compared to the consensus estimate of $0.26 million. Spero Therapeutics had a return on equity of 35.58% and a net margin of 24.90%.

Insiders Place Their Bets

In other Spero Therapeutics news, insider Esther Rajavelu sold 25,240 shares of the firm’s stock in a transaction on Monday, May 4th. The stock was sold at an average price of $2.51, for a total value of $63,352.40. Following the sale, the insider directly owned 986,851 shares in the company, valued at approximately $2,476,996.01. This trade represents a 2.49% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 2.90% of the stock is owned by corporate insiders.

Institutional Trading of Spero Therapeutics

Several hedge funds have recently bought and sold shares of the company. GSK plc acquired a new position in Spero Therapeutics during the 4th quarter valued at about $21,414,000. Arrowstreet Capital Limited Partnership bought a new stake in Spero Therapeutics during the 3rd quarter valued at $283,000. OMERS ADMINISTRATION Corp bought a new stake in Spero Therapeutics during the 4th quarter valued at $306,000. Squarepoint Ops LLC acquired a new position in Spero Therapeutics during the 4th quarter worth $278,000. Finally, Shay Capital LLC bought a new position in shares of Spero Therapeutics in the third quarter worth $120,000. 25.60% of the stock is currently owned by institutional investors.

About Spero Therapeutics

Spero Therapeutics is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel therapies to address multidrug‐resistant bacterial infections. Headquartered in Boston, Massachusetts, the company aims to advance a pipeline of oral and intravenous antibiotic candidates designed to treat serious infectious diseases that pose significant public health challenges.

The company’s lead candidate, tebipenem HBr, is an oral carbapenem antibiotic being developed for the treatment of complicated urinary tract infections caused by resistant Gram‐negative pathogens.